Almost two-thirds of CML patients maintained a major molecular response and quality of life gains

Discontinuation of tyrosine kinase inhibitor (TKI) therapy allowed almost two-thirds of patients with chronic myeloid leukemia (CML) to maintain a major molecular response (MMR) for at least 3 years, most of whom also remained in treatment-free remission (TFR) at the same time point, a prospective, non-randomized trial found.

In a cohort of 171 evaluable patients, 65.5% of patients previously treated with a TKI maintained an MMR at 3 years, while the rate of successful TFR was 60.8%, Ehab Atallah, MD, Medical College of Wisconsin, Milwaukee, and colleagues reported in JAMA Oncology. Discontinuation of treatment was also associated with clinically meaningful improvements in fatigue, depression, diarrhea, and sleep disturbance for many patients.

“The LAST (Life After Stopping TKIs) study was the largest and only prospective US-only TKI discontinuation study to date,” Atallah and colleagues wrote. “Our results provide important new information to inform the discussion between patients with CML and clinicians about the risks and benefits of TKI discontinuation and the potential to assess TKI cessation more accurately.”

LAST Study

LAST study participants had been taking either imatinib, dasatinib, nilotinib, or bosutinib (Bosuli, Pfizer) for 3 or more years, with continuous documented BCR-ABL less than 0.01% by polymerase chain reaction (PCR) for at least 2 years and no evidence of TKI resistance prior to study enrollment.

“Patient-reported outcomes were assessed monthly for the first 6 months, at 8 and 12 months, then every 6 months until 36 months,” Atallah and colleagues wrote.

Over a median follow-up of 41.6 months, slightly over one-third of patients at 34.5% experienced a molecular recurrence (MRec) and slightly over 39% restarted TKI therapy, with a median time to MRec of 4 months (range, 1.5-41.3 months). Proportionately, MRec occurred in over half of patients in less than 3 months to up to 6 months after treatment discontinuation; very few patients experienced MRec 2 to 3 years after TKI discontinuation.

The study authors noted that 16.4% of patients had detectable BCR-ABL1 transcripts by real-time quantitative PCR (RQ-PCR) while the rest of patients had undetectable BCR-ABL1 transcripts by the same PCR technique.

“Molecular recurrence for patients with detectable BCR-ABL1 transcripts by RQ-PCR was 50.0%,” they wrote and added that the molecular recurrence rates for patients with undetectable BCR-ABL1 transcripts by RQ-PCR, but which were detectable on droplet digital PCR (ddPCR), were higher at 64.3%.

For patients whose BCR-ABL1 transcripts were undetectable by both RQ-PRC and ddPCR, the MRec rate was only 10.3% (P ≤0.001).

Indeed, “[d]etectable BRC-ABL1 by either method at discontinuation was associated with a significantly higher risk of MRec,” the study authors noted, at a Hazard Ratio (HR) of 10.11 (95% CI, 3.35-30.49; P<0.001).

Patient Reported Outcomes

LAST study investigators were the first to use the National Institutes of Health PROMIS measure to assess patient-reported outcomes (PROs). Before TKI therapy was stopped, 15.7% of patients reported at least moderately severe fatigue.

“Fatigue improved after TKI discontinuation and the improvement was sustained over time,” Atallah and colleagues noted, such that by 12 months, 80.4% of patients in TFR reported a clinically meaningful improvement in fatigue, which worsened once TKI treatment was restarted.

Similarly, 17.4% of patients had at least moderately severe diarrhea prior to TKI discontinuation.

“Mean diarrhea scores improved after TKI discontinuation,” the study authors wrote, in that again by 12 months, 87.5% of patients in TFR had a clinically meaningful improvement in diarrhea scores, although scores again worsened after TKI therapy was restarted.

Depression scores also improved with some 19.8% of patients having at least moderately severe depression prior to treatment discontinuation, which showed improvement after TKI discontinuation in over one-third of patients in TFR at the one-year PRO assessment point.

Some 14% of patients also reported having sleep disturbances while taking a TKI; after treatment had been discontinued, the mean sleep disturbance score improved in about 21% of TFR patients.

Lastly pain interference—meaning the extent to which pain affected daily life—was reported as moderately severe in about 20% of patients as well.

However, in this case, changes in the mean pain interference scores were not statistically or clinically significant following TKI discontinuation.

As the study authors pointed out, unlike previous reports, there did not appear to be an increase in musculoskeletal pain following TKI discontinuation in the current study as very few patients reported an increase in how pain interfered with daily life.

The authors acknowledged that ddPCR testing is not widely available right now in the U.S. “[But] if available, a less-intensive monitoring approach for patients with undetectable BCR-ABL1 at TKI cessation by ddPCR and with undetectable BCR-ABL1 at 3 months may be justified,” the authors suggested—for example, every 3 months given the low risk for MRec.

However, for all other patients, the current schedule of monitoring every month should remain standard practice, they advised.

“The LAST study demonstrates that patients with undetectable BCR-ABL1 by ddPCR had a very high chance of maintaining MMR, with modest improvements in PROs,” researchers concluded.

Limitations of the study include the fact that it was not a randomized trial and thus may not provide sufficient evidence for causal conclusions.

Safety of TKI Discontinuation

Commenting on the findings, Theodore Braun, MD, PhD, and Brian Druker, MD, both from the Oregon Health & Science University in Portland, Oregon, pointed out the safety of TKI discontinuation has now been evaluated in almost 4000 CML patients in deep molecular remission.

“Collectively, these trials showed that such patients have an approximately 50% chance of disease recurrence, with the remaining 50% of patients experiencing long-term TFR,” Braun and Druker wrote.

With the current LAST study, findings provide “objective evidence” that quality of life measures also improve once patients are off therapy, the editorialists noted. Importantly, as well, the new PCR technique, ddPCR, which is more sensitive in its ability to detect BCR-ABL1 transcripts, more accurately identified those patients with the greatest likelihood of achieving a TFR status.

“Because ddPCR is only available in a few centers and this was a relatively small study, additional validation studies will be necessary for these findings to be generalized,” the editorialists cautioned. However, if validated, the question then arises, what is it about these patients that allows them to achieve TFR?

“Through an understanding of the mechanisms that allow TFR, it might be possible to develop strategies to allow more patients with CML to get to TFR and enjoy the benefits of being off therapy,” Braun and Druker concluded.

  1. Treatment-free remission was achieved for a large proportion of CML patients when TKI therapy was stopped, and patients remained in remission for at least 3 years with no therapy.

  2. Patient-reported that outcomes including fatigue, depression, diarrhea, and sleep disturbances significantly improved after discontinuation of TKI therapy, all of which worsened when treatment was restarted.

Pam Harrison, Contributing Writer, BreakingMED™

Atallah reported receiving personal fees from Novartis, Bristol Myers Squibb and Takeda as well as research support from Novartis and Takeda.

Druker reported receiving personal fees from Aileron Therapeutics, Therapy Architects, Amgen, Aptos Biosciences, Iberian Therapeutics, Blueprint Medicines, the Burroughs Welcome Fund, Cepheid, GRAIL, Enliven Therapeutics, the Novartis CML molecular monitoring steering committee, the RUNX1 Research Program, VBL Therapeutics, Viscera Parma, Vivid Biosciences, Colene, Gilead Sciences, and ICON; and additional support from Enliven Therapeutics, Novartis, Bristol Myers Squibb, and Pfizer; he also reports a patent with royalties paid from Novartis for a treatment for gastrointestinal stoma tumors.

Braun had no conflicts of interest to disclose.

Cat ID: 466

Topic ID: 78,466,730,466,192,925